Tim Jasper Knotnerus, Chief Executive Officer at AgomAb Therapeutics, bought AGMB on Oct 5, 2026
Data as of Oct 16
▲ BUY$50.9K6,000 shares at $8.48Tim Jasper Knotnerus Chief Executive OfficerAGMB AgomAb Therapeutics NV
- Traded
- Oct 5, 2026
- Disclosed
- Oct 7, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
AGMB since disclosure
−5.9%
Similar stocks (XLV) since disclosure
+4.7%
XLV — its sector index fund
Change in closing price from Oct 7, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
- Not enough evidence · In past tests: 8.0 percentage points better than similar stocks over 3 months · 2,952 tries
- Not enough evidence · In past tests: 3.6 percentage points better than similar stocks over 3 months · 2,178 tries
- Not enough evidence · In past tests: 2.0 percentage points better than similar stocks over 3 months · 1,426 tries
Other trades in the same filing
- ▲ BUYTim Jasper Knotnerus Chief Executive OfficerAGMB AgomAb Therapeutics NV$43.5Kdisclosed Oct 7 · filed 1 day after the trade 1 rule fired